ZYME — Stock Film
STOCK FILMSCENE 1/11ZYME · $26.57
Stock Expert AI presents
ZYME
Zymeworks Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Zymeworks Inc. A quick introduction.

On the stock market since 2017, it operates in the world of health and science. It has 243 employees. Now — the numbers.

on the stock market since 2017
243 employees
$1.8B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.8.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
62%Milestone Revenue
Milestone Revenue 62%Option Exercise Fee 18%Research Support Payments and Other Service 14%Royalty 6%
62% of all revenue comes from a single line: Milestone Revenue.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 41% a year over the last 4 years. Red columns mark years that ended in a loss.

$26.7M
2021
$412.5M
2022
$76M
2023
$76.3M
2024
$106M
2025
In the vault right now:
$0
DEBT: $18.3M
At this pace, that money lasts about 2.8 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
35
weak

Clearly below the class average.

FINANCIAL STRENGTH
13
very weak

Clearly below the class average.

VALUATION
66
strong

Clearly above the class average — a step short of the very top.

GROWTH
77
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
70
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 26% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $106.0M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 46 buys and 20 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $43.4063% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $81.1M against $106.0M in annual sales.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 13/100.

3
THE RISKS · 3/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 35/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ZYME sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ZYME is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film